@article{757c408310904545b934c9883ccfe24d,
title = "Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance",
abstract = "Cytotoxicity of tumor-specific T cells requires tumor cell-to-T cell contact-dependent induction of classic tumor cell apoptosis and pyroptosis. However, this may not trigger sufficient primary responses of solid tumors to adoptive cell therapy or prevent tumor antigen escape-mediated acquired resistance. Here we test myxoma virus (MYXV)-infected tumor-specific T (TMYXV) cells expressing chimeric antigen receptor (CAR) or T cell receptor (TCR), which systemically deliver MYXV into solid tumors to overcome primary resistance. In addition to T cell-induced apoptosis and pyroptosis, tumor eradication by CAR/TCR-TMYXV cells is also attributed to tumor cell autosis induction, a special type of cell death. Mechanistically, T cell-derived interferon γ (IFNγ)-protein kinase B (AKT) signaling synergizes with MYXV-induced M-T5-SKP-1-VPS34 signaling to trigger robust tumor cell autosis. CAR/TCR-TMYXV-elicited autosis functions as a type of potent bystander killing to restrain antigen escape. We uncover an unexpected synergy between T cells and MYXV to bolster solid tumor cell autosis that reinforces tumor clearance.",
keywords = "acquired resistance, autosis, CAR-T cells, myxoma virus",
author = "Ningbo Zheng and Jing Fang and Gang Xue and Ziyu Wang and Xiaoyin Li and Mengshi Zhou and Guangxu Jin and Rahman, {Masmudur M.} and Grant McFadden and Yong Lu",
note = "Funding Information: This work was supported by the National Cancer Institute (NCI; 1R37CA251318-01, 1R01CA248111-01A1, R01CA258477-01, and 1R01CA264102-01) and CPRIT Scholar (RR210067). We thank Amanda M. Weisskoff for editing assistance. Conceptualization, Y.L.; investigation, Y. L. N.Z. and J.F.; methodology, G.X. and Z.W.; resources, M.M.R. and G.M.; statistical analysis, X.L. M.Z. and G.J.; writing, Y.L. and N.Z.; funding acquisition, Y.L. Previously, G.M. was a co-founder and equity holder of OncoMyx Therapeutics, but it was operationally dissolved in July 2022, and its assets no longer hold any value. G.M. continues to hold patents related to use of transgene-armed MYXV to treat cancer. Funding Information: This work was supported by the National Cancer Institute ( NCI ; 1R37CA251318-01 , 1R01CA248111-01A1 , R01CA258477-01 , and 1R01CA264102-01 ) and CPRIT Scholar ( RR210067 ). We thank Amanda M. Weisskoff for editing assistance. Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",
year = "2022",
month = sep,
day = "12",
doi = "10.1016/j.ccell.2022.08.001",
language = "English (US)",
volume = "40",
pages = "973--985.e7",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "9",
}